Lantern Pharma Inc. (LTRN): Cash & Equivalents
$4.42M
As of 2025-12-31
$6.66M
As of 2026-06-30
-50.8%
3-year compound annual growth
-25.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.42M | -41.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $7.51M | -65.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $21.94M | -41.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $37.20M | -27.8% | 2024-03-18, Balance as of period end |
| 2021-12-31 | $51.52M | +167.9% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $19.23M | n/m | 2022-03-10, Balance as of period end |
| 2019-12-31 | $1.23M | n/a | 2021-03-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $4.42M | -41.1% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $10.71M | +339.9% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $6.35M | +124.0% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $10.28M | -35.8% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $2.20M | +238.6% |
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $5.00M | n/a |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $10.70M | +64.6% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $334.0K | -82.6% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $4.66M | -75.8% |
Compare LTRN, DCOY, MIRA, MTVA side by side · Screen every company in Pharmaceutical Preparations ↗